Are you or a loved one living with early symptoms of Alzheimer’s disease or mild cognitive impairment?

Learn more about the POLARIS-AD study, for people in the early stages of Alzheimer’s Disease (AD).
POLARIS-AD will examine whether a study drug called AR1001 may help slow AD progression.

Who can join the POLARIS-AD study?
Study participants may be able to join the study if they meet the following requirements:

Are 55 to 90 years old.
Have signs and symptoms associated with the mild stage of Alzheimer’s, such as some memory, planning, and organizational issues. However, they can complete most daily tasks independently
Have a care partner who can accompany them to study visits.

Other study requirements will apply.

Study participants receive at no cost:

Access to the study drug
For the first year of the study, half of participants will receive placebo, which has no active ingredients.
For the next 1 year, all participants will be able to receive the study drug.
Study support and monitoring by a healthcare team
The opportunity to help advance AD research

For the first year of the study, half of participants will receive placebo, which has no active ingredients.
For the next 1 year, all participants will be able to receive the study drug.

For more information, visit https://earlyalzheimersdiseasestudy.com/FCA